Tag: Kevzara
Regeneron, Sanofi restructure Kevzara, Praluent collaboration
Under the new agreement, Paris-based Sanofi would gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent, while Tarrytown’s Regeneron would gain sole U.S. rights to Praluent.
Regeneron drug for rheumatoid arthritis approved in Europe
The European Commission approved the use of Kevzara under certain conditions to treat adults with moderately to severely active rheumatoid arthritis.
FDA approves Regeneron drug Kevzara for rheumatoid arthritis
The new human antibody drug will be used to treat a chronic inflammatory disease that affects about 1.3 million Americans.